Supplementary Materials

Accelerated cartilage regeneration via chondrocyte metabolic reprogramming using nano-steroid-conjugated mesenchymal stem cells in osteoarthritis

Jong Yeong Lee, Jun Young Park, In Ah Kwon, Su Hyun Lim, Ki Bum Kim, Jun-Young Park, Youn Joo Kang, Sang-Hyun Kim, Dongwoo Khang, Jin Kyeong Choi

Corresponding author: Dongwoo Khang and Jin Kyeong Choi

E-mail: dkhang@gachon.ac.kr; jkchoi@jbnu.ac.kr

Files include:

Materials and Methods

Table S1 to S3

Figures S1 and S8

References

Materials and methods

Drug release profile

MSC-Au-Steroid complexes (1×10^6 cells) were individually prepared for each time point (0 h, 1 h, 6 h, and 12 h), and all samples were subsequently lyophilized for more than 24 hours to ensure stability. The dried complexes were dissolved in 100 μ L of methanol and further diluted with an ACN:DW (50:50) mixture prior to analysis. Each sample was analyzed using a UPLC system (ACQUITY UPLC H-Class PLUS; Waters) equipped with a C18 column (1.7 μ m, Waters) operated at 50 °C. The mobile phase conditions were programmed with a stepwise gradient, beginning with 100% DW, gradually increasing the ACN concentration over a defined period, and then returning to the initial condition for re-equilibration. The TA peak was consistently detected at 241 nm with a retention time (RT) of 28–32 min. All samples and mobile phases were filtered through a 0.2 μ m PTFE-D filter prior to injection. Through this procedure, the drug release profile of MSC-Au-Steroid complexes was quantitatively evaluated across different time points.

Transmission Electron Microscope (Bio-TEM)

Human primary chondrocytes derived from OA patients were cultured for 24 h with or without IL-1β, MSCs, Au–Steroid, or MSC–Au–Steroid, following the method previously described. After incubation, the cells were fixed in a mixture of 2% glutaraldehyde (GA, EM grade) and 2% paraformaldehyde (FA, EM grade) prepared in 0.05 M sodium cacodylate buffer (pH 7.2) at 4 °C for 2 h. A secondary fixation step was performed using 1% osmium tetroxide for 1 h and 30 min. The fixed samples were rinsed three times with distilled water and incubated with 0.5% uranyl acetate at 4 °C for 30 min in the dark. After dehydration through graded ethanol, the specimens were treated with 100% propylene oxide and embedded in Embed 812 resin, followed by polymerization at 60 °C for 48 h. Ultrathin sections were prepared using an

ultramicrotome (UC7, Leica), mounted on copper grids, and visualized with a transmission electron microscope (H-7650, Hitachi).

DMM-induced mouse model of OA

Mice were under general anesthesia with 1.5–2% isoflurane (657801261, Hana pharm) prior to surgery. Hair around the knee was removed using an electric razor, and the area was disinfected three times alternately with 70% ethanol and povidone-iodine solution (A11A1720B0030, Dongin pharm). A heating pad (37°C) was used to prevent hypothermia during surgery. An approximately 5–7 mm anteromedial incision was made on the left knee to expose the knee joint. The medial meniscus and the medial meniscus-tibialis ligament were transected to induce medial meniscus destabilization. After suturing the surgical site, 20 mg/kg of amoxicillin (A8523, Sigma) was injected subcutaneously to prevent joint infection, and the induction period was continued for 10 weeks. MSC (1×10^6 cells), Au-Steroid (3 mg/kg), and conjugated MSC (1×10^6 cells)-Au-Steroid (3 mg/kg) were administered starting from the fourth week after induction, once every week. Each group of mice was divided into five groups, with seven mice per group. At week 10, mice were sacrificed, and joint tissues were collected and fixed in 4% formaldehyde for pathological examination and micro-CT analysis.

DDIT4 Overexpression Plasmid Construction and Transfection

Full-length human DDIT4 cDNA was cloned into the pcDNA3.1 vector under the CMV promoter (V79020, Thermo Fisher). The integrity and orientation of the insert were confirmed by Sanger sequencing. The resulting plasmid was transformed into E. coli DH5α (18265017, Thermo Fisher) and cultured under ampicillin selection. Plasmids were amplified and purified using an Endofree plasmid kit (12362, Qiagen). Primary human chondrocytes (passages 2–3) were seeded and cultured until they reached 70–80% confluence. For transfection, 2 μg of

plasmid DNA per well (6-well plate) was mixed with Lipofectamine 3000 reagent (L3000015, Thermo Fisher) at a 1:3 DNA-to-reagent ratio, following the manufacturer's protocol. Cells were incubated at 37°C in 5% CO₂ for 48 h.

T cell Co-culture Assay

CD4⁺CD25⁻ effector T cells (Teff) were negatively isolated from PBMCs of OA patients using magnetic bead separation (Miltenyi Biotec) according to the manufacturer's instructions. Regulatory T cells (Tregs; CD4⁺CD25⁺, 130-091-301, Miltenyi Biotec) were obtained from each experimental group (Untreated, MSC, Au-Steroid, MSC-Au-Steroid) by flow cytometry sorting. Teff and Tregs were co-cultured at a 1:1 ratio (1 × 10⁵ cells each per well) in 96-well round-bottom plates. Control wells contained Teff cultured alone under identical conditions. Cells were stimulated with 1 μg mL⁻¹ anti-CD3 (555336, BD Biosciences) for 72 h at 37°C in 5% CO₂. T cell proliferation was measured by BrdU incorporation assay (Roche) according to the manufacturer's protocol. Culture supernatants were collected at the end of the incubation period, and IFN-γ secretion was quantified using a human IFN-γ ELISA kit (eBioscience).

Table S1. Quantification of TA and conjugation efficiency of AuS-TA prior to attachment to Edu-MSCs. The data include the mass of conjugated TA per Edu-MSCs measured by UV–vis (246 μ g \pm 30) and UPLC (241.13 μ g \pm 0.82), as well as the final TA:AuS ratio after Edu-MSCs conjugation (1 : 2.39 \pm 0.42).

| Edu-MSC-AuS-TA | | |
|--|-------------------------------|---------------------------|
| | UV-vis | UPLC |
| Percentage of conjugated TA per AuS (Before conjugated Edu-MSCs) | 41.7% (± 7.20) | - |
| Mass of conjugated TA per Edu-MSCs (1 X 10 ⁶) | $246 \ \mu g \ (\pm \ 30.00)$ | $241.13~\mu g~(\pm~0.82)$ |
| Final TA: AuS ratio (After conjugated Edu-MSCs) | 1: 2.39 (± 0.42) | - |

Table S2. Clinical characteristics of enrolled patients with degenerative osteoarthritis

Kellgren-Lawrence (K-L) Grading System for Knee Osteoarthritis: The K-L grade assesses knee OA severity using X-ray imaging (1).

Grade 0 (No OA): Normal

Grade 1 (Doubtful OA): Possible osteophytes

Grade 2 (Mild OA): Definite osteophytes, possible joint space narrowing

Grade 3 (Moderate OA): Medium osteophytes, definite joint space narrowing

Grade 4 (Severe OA): Large osteophytes, severe joint space narrowing, osteosclerosis

| Patient ID | Sex | Age | K-L grade |
|---------------|--------|-----|-----------|
| 1 | Female | 67 | IV |
| 2 | Female | 63 | IV |
| 3 | Female | 79 | IV |
| 4 | Male | 67 | III |
| 5 | Female | 70 | IV |
| 6 | Female | 58 | IV |
| 7 | Female | 80 | IV |


Table S3. Forward and reverse primer sequence Human

| Gene | Forward primer (5'>3') | Reverse primer (5'>3') |
|------------|--------------------------------|-----------------------------------|
| Tnfa | GAGCTGAGAGATAACCAGCTGGTG | CAGATAGATGGGCTCATACCAGG G |
| $Il1\beta$ | GCT GAT GGC CCT AAA CAG ATG AA | TGA AGC CCT TGC TGT AGT GGT G |
| Il6 | CCC CTG ACC CAA CCA CAA AT | CAT TTG CCG AAG AGC CCT CA |
| MMP1 | TGG ACC TGG AGG AAA TCT TG | AGT TCA TGA GCT GCA ACA CG |
| MMP3 | TTC CTT GGA TTG GAG GTG AC | TGC CAG GAA AGG TTC TGA AG |
| ММР9 | GCC ACT ACT GTG CCT TTG AGT C | CCC TCA GAG AAT CGC CAG TAC T |
| MMP13 | CTATGGTCCAGGAGATGAA | AGAGTCTTGCCTGTATCCTC |
| Col2a1 | TCTACCCCAATCCAGCAAAC | GTTGGGAGCCAGATTGTCAT |
| Sox9 | ACTTGCACAACGCCGAG | CTGGTACTTGTAATCCGGGTG |
| Ddit4 | GTT TGA CCG CTC CAC GAG CCT | GCA CAC AAG TGT TCA TCC TCA GG |
| Ptpn1 | TGT CTG GCT GAT ACC TGC CTC T | ATC AGC CCC ATC CGA AAC TTC C |
| Pten | TGA GTT CCC TCA GCC GTT ACC T | GAG GTT TCC TCT GGT CCT GGT A |
| Atg5 | GCA GAT GGA CAG TTG CAC ACA C | GAG GTG TTT CCA ACA TTG GCT CA |
| β-actin | AGAGCTACGAGCTGCCTGAC | AGCACTGTGTTGGCGTACAG |

| Gene | Forward primer (5'>3') | Reverse primer (5'>3') |
|--------------|--------------------------------------|--------------------------------------|
| Tnfa | GGC AGG TCT ACT TTG GAG TCA TTG C | ACA TTC GAG GCT CCA GTG AAT TCG G |
| ΙΙ1β | CCA AAA GAT GAA GGG CTG CTT | TGC TGC TGC GAG ATT TGA AG |
| 116 | TCC AGT TGC CTT CTT GGG AC | GT CTG TTG GGA GTG GTA TC |
| Ifnγ | TCAAGTGGCATAGATGTGGAAGA A | TGGCTCTGCAGGATTTTCATG |
| Il17a | CTCAAAGCTCAGCGTGTCCAAAC A | TATCAGGGTCTTCATTGCGGTGG A |
| Adamts4 | CAT CCG AAA CCC TGT CAA CTT G | GCC CAT CAT CTT CCA CAA TAG C |
| Adamts5 | GCC ATT GTA ATA ACC CTG CAC C | TCA GTC CCA TCC GTA ACC TTT G |
| Col2a1 | CAC ACT GGT AAG TGG GGC AAG ACC G | GGA TTG TGT TGT TTC AGG GTT CGG G |
| Sox9 | ATG CTA TCT TCA AGG CGC TG | GAC GTC GAA GGT CTC AAT GT |
| Aggrecan | CTG TCT TTG TCA CCC ACA CAT | GAA GAC GAC ATC ACC ATC CAG |
| Mmp1 | CCT TCC TTT GCT GTT GCT TC | AGC CCA AAT AAC TGC TGC AT |
| <i>Мтр3</i> | AAG TTC CTC GGG TTG GAG AT | TTT CAA TGG CAG AAT CCA CA |
| Mmp9 | ACC ACA TCG AAC TTC GA | CGA CCA TAC AGA TAC TG |
| <i>Mmp13</i> | TGA TGG ACC TTC TGG TCT TCT GG | CAT CCA CAT GGT TGG GAA GTT CT |
| Cxcl12 | GGA GGA TAG ATG TGC TCT GGA AC | AGT GAG GAT GGA GAC CGT GGT G |
| Argl | AGG CGC TGT CAT CGA TTT CT | TGG AGT CCA GCA GAC TCA AT |
| Cd206 | CTC TGT TCA GCT ATT GGA CGC | CGG AAT TTC TGG GAT TCA GCT TC |
| 1110 | AGG CGC TGT CAT CGA TTT CT | ATG GCG TGA GGG AGA GCA TAG |

β-actin ACC CTA AGG CCA ACC GTG AA

 $\begin{array}{c} \text{ATG GCG TGA GGG AGA GCA} \\ \text{TAG} \end{array}$






Figure S1. (**A-B**) Standard calibration curve for the quantification of Au and TA analyzed by UV–vis. (**C**) Transmission electron micrographs of Au-Steroid with energy-dispersive X-ray spectroscopy mapping (EDS mapping) showing the distribution of Au (yellow), S (red; from PEG), and F (blue; from Steroid). Scale bar (white) = 100 nm. (**D**) Standard calibration curve for the quantification TA analyzed by UPLC. (**E**) Time-dependent release profile of TA from MSC-Au-Steroid. Data are presented as mean \pm SD (n = 3).




Figure S2. (A–H) OA chondrocytes were treated with IL-1 β (10 ng mL⁻¹) for 24 h with or without MSCs (1 × 10⁴ cells), Au-Steroid (500 ng mL⁻¹), MSC plus Au-Steroid co-treatment,

or MSC-Au-Steroid conjugates (n = 3). (A) Western blot analysis of matrix metalloproteinases (MMP-1 and MMP-3). (B) Densitometric quantification of relative MMP protein levels. (C) Representative real-time ECAR traces of OA chondrocytes following sequential injections of glucose, oligomycin, and 2-deoxy-D-glucose (2-DG), with derived parameters for glycolytic capacity and glycolytic reserve. (D) Representative real-time OCR traces in response to oligomycin, FCCP, and Rot/AA, with bar graphs summarizing basal respiration and ATP-linked respiration. (E) Additional ECAR recordings for confirmation of glycolytic responses to glucose, oligomycin, and 2-DG. (F) Bar graphs summarizing glycolysis, glycolytic capacity, and glycolytic reserve. (G) Additional OCR recordings illustrating mitochondrial respiratory responses to oligomycin, FCCP, and Rot/AA. (H) Bar graphs summarizing basal and maximal respiratory capacity and ATP production. Data are presented as the mean ± SEM. ****p < 0.0001, ***p < 0.001, **p < 0.001, **p < 0.01, and *p < 0.05.





Figure S3. (A-B) OA chondrocytes were stimulated with IL-1β (10 ng mL⁻¹) for 24 h in the presence or absence of MSCs (1 × 10⁴ cells), Au–Steroid (500 ng mL⁻¹), or MSC–Au–Steroid conjugates (1 \times 10 4 cells and 500 ng mL⁻¹) (n = 3). (A) Flow cytometric analysis of mitochondrial mass and mitochondrial ROS production in OA chondrocytes labeled with MitoTracker Green (mitochondrial content) and MitoSOX Red (mitochondrial ROS). (B) Mean fluorescence intensity (MFI) bar graphs showing mitochondrial mass (MitoTracker Green) and mitochondrial ROS levels (MitoSOX Red). (C-E) OA chondrocytes were transfected with control siRNA or DDIT4-specific siRNA for 48 h, followed by stimulation with IL-1 β (10 ng mL⁻¹) in the presence or absence of MSCs (1 × 10⁴ cells), Au–Steroid (500 ng mL⁻¹), or MSC-Au-Steroid conjugates (n = 3). (C) Western blot analysis of DDIT4 expression in chondrocytes transfected with control or DDIT4 siRNA. (D) Western blot analysis of MMP3 and MMP13 protein levels in control or DDIT4-silenced cells. (E) Quantification of the relative protein band intensities. (F) Western blot analysis of p-RAPTOR, RAPTOR, p-P70S6, P70S6, and DDIT4 expression in OA chondrocytes treated with MSCs, Au-Steroid, MSC-Au-Steroid, or DDIT4 vector under IL-1β stimulation. (G) Bar graphs showing the relative protein expression ratios of p-RAPTOR/RAPTOR, p-P70S6/P70S6, and DDIT4 normalized to β -actin. Data are presented as the mean \pm SEM. ***p < 0.001, **p < 0.01. and *p < 0.05.







Figure S4. (A) Schematic illustration of the repeated-dose toxicity study. C57BL/6 mice received intraperitoneal injections of MSCs (1 × 10⁶ cells), Au–Steroid (3 mg kg⁻¹), or MSC-Au-Steroid conjugates (1 × 10⁶ cells and 3 mg kg⁻¹) three times per week for 4 weeks to evaluate repeated-dose toxicity (n = 5). (B) Changes in body weight over the course of treatment. (C) Representative gross images of major organs collected from each treatment group. (D) Representative hematoxylin and eosin (H&E)-stained sections of the colon, kidney, liver, spleen, lung, and lymph node showing no histopathological abnormalities (×200 magnification). (E) Hematological analyses including red blood cell (RBC) count, hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet (PLT) count, white blood cell (WBC) count, and differential leukocyte counts (neutrophils, lymphocytes, monocytes, eosinophils, and basophils). (F) Serum biochemical analyses including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T-bil), total protein (TP), albumin (Alb), albumin-to-globulin ratio (A/G), blood urea nitrogen (BUN), and creatinine (Crea). (G) Flow cytometric analysis of T-cell subsets (CD3+, CD4+, and CD8+ T cells) in the kidney, liver, spleen, lung, and lymph node. No significant abnormalities were detected across groups, confirming the absence of systemic toxicity following repeated dosing... Data are presented as the mean \pm SEM.






Figure S5. (A-E) C57BL/6J mice were injected intra-articularly with 0.75 mg MIA and then treated via intraperitoneal injection with MSC (1×10⁶ cells), Au-Steroid (3 mg/kg), or MSC $(1\times10^6 \text{ cells})$ -Au-Steroid (3 mg/kg) (n = 4/group per experiment). (A) Osteophyte development, subchondral bone plate (SBP) thickness, and synovitis score in the indicated mice 28 days after MIA induction. (B) Micro-CT analysis results of bone volume fraction (BV/TV), bone surface to bone volume ratio (BS/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp). (C) Gene expression of inflammatory cytokines ($Tnf\alpha$, $Il1\beta$, Il6, Ifnγ, and Il17a), chemokine (Cxcl12), and (**D**) MMPs (Mmp1, Mmp3, Mmp9, and Mmp13) in the knee joints excised on day 28 was analyzed using qPCR. (E) Protein expression of MMPs was determined using western blotting (left panel) and bar graphs of relative intensities (right panel). (F-M) (F) Experimental design for the surgically induced DMM OA mouse model. C57BL/6J mice were subjected to DMM surgery and monitored for 8 weeks. Treatments with MSC (1×106 cells), Au-Steroid (3 mg/kg), or MSC (1×106 cells)-Au-Steroid (3 mg/kg) were administered intraperitoneally once a week starting at 4 weeks post-surgery, and analyses were performed at day 56 (n = 4/group per experiment). The mice were divided into five groups (n= 4 mice. (G) Flow cytometry analysis of digested knee joint tissues on day 56. Human MSCs were identified as mouse CD45⁻ human CD73⁺ cells. Representative FACS plots (left) and quantification of delivered MSCs in joint tissues (right). (H-I) Histological evaluation of knee joints after DMM induction. Safranin O staining was used to assess proteoglycan loss in articular cartilage, and H&E staining was used to evaluate synovitis (×200 magnification). Representative images are shown (H), along with OARSI scores (I). (D) OARSI score in the indicated mice 28 days after MIA induction. (J-K) Representative micro-CT images (J) and quantitative micro-CT analysis (K) of subchondral bone in DMM joints. Bone mineral density (BMD) was significantly improved in MSC-Au-Steroid-treated mice compared with other treatment groups. (L) Quantitative histological analysis of articular cartilage, including

Osteophyte development, subchondral bone plate (SBP) thickness, and synovitis score, performed on Safranin O-stained sections. (**M**) Micro-CT analysis results of bone volume fraction (BV/TV), bone surface to bone volume ratio (BS/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp). Data are presented as the mean \pm SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05




Figure S6. C57BL/6J mice were intra-articularly injected with 0.75 mg MIA to induce OA and subsequently treated via intraperitoneal injection with MSCs (1 × 106 cells), Au–Steroid (3 mg kg⁻¹), or MSC–Au–Steroid conjugates (1 × 106 cells and 3 mg kg⁻¹) (n = 4). (**A**) Real-time oxygen consumption rate (OCR) profiles of mouse knee joints in response to oligomycin, FCCP, and Rot/AA, with bar graphs showing basal respiration and ATP-linked respiration. (**B**) Real-time extracellular acidification rate (ECAR) profiles of mouse knee joints following sequential injections of glucose, oligomycin, and 2-DG, with corresponding bar graphs illustrating glycolytic capacity and glycolytic reserve. (**C**) Western blot analysis of mTOR and its downstream mTORC1 target proteins, with quantification of relative band intensities. (**D**) Western blot analysis of AMPKα and DDIT4 expression, with bar graphs representing relative protein intensities.







Figure S7. (**A**) Representative flow cytometry plots and (**B**) bar charts showing the percentages of F4/80⁺CD11b⁺ (macrophages), F4/80⁺CD163⁻ (M1 macrophages), and F4/80⁺CD163⁺ (M2 macrophages) in knee joint cells. (**C**) Gene expression M2 macrophages marker (Arg1, II10, and Cd206) in the knee joints excised on day 28 was analyzed using qPCR. Data are presented as the mean \pm SEM. ****p < 0.0001, and **p < 0.01.








- αCD3
 - αCD3+MSC
- αCD3+Au-Steroid
 αCD3+MSC-Au-Steroid
- MILOGOA








Figure S8. (**A**) Representative histograms (left) and mean fluorescence intensity (MFI) bar graphs (right) showing mitochondrial ROS levels in PBMCs from OA patients. T cells were stimulated with anti-CD3 (1 μ g mL⁻¹) and treated with MSCs (1 × 10⁴ cells), Au–Steroid (500 ng mL⁻¹), or MSC–Au–Steroid conjugates (1 × 10⁴ cells and 500 ng mL⁻¹) for 72 h (n = 7). Cells were labeled with MitoSOX Red and analyzed by flow cytometry. (**B-C**) PBMCs isolated

from healthy donors were activated with anti-CD3 (1 µg mL⁻¹) in the presence or absence of Mito-TEMPO (500 μg mL⁻¹), MSCs (1 × 10⁴ cells), Au–Steroid (500 ng mL⁻¹), or MSC–Au– Steroid conjugates (1 \times 10⁴ cells and 500 ng mL⁻¹) for 72 h (n = 3). Representative flow cytometry plots and corresponding bar graphs display the proportions of CD4+ T cells expressing TNF- α , IFN- γ , and IL-17A. (**D-E**) PBMCs obtained from healthy donors (H, n = 3) or OA patients (OA, n = 3) were activated with anti-CD3 (1 µg mL⁻¹) and cultured for 72 h in the presence or absence of MSCs (1 × 10⁴ cells), Au–Steroid (500 ng mL⁻¹), MSC–Au–Steroid $(1 \times 10^4 \text{ cells and } 500 \text{ ng mL}^{-1})$, or Mito-TEMPO (500 $\mu g \text{ mL}^{-1}$). Representative flow cytometry plots (D) and summarized bar graphs (E) show the frequency of CD4+ T cells producing TNF-α, IFN-γ, and IL-17A. (**F-G**) Negatively magnetic-bead–purified CD4+CD25⁻ effector T cells (Teff) isolated from OA patients were cultured alone or co-cultured at a 1:1 ratio with flow cytometry-sorted CD4+CD25+ regulatory T cells (Tregs) derived from each treatment group (Untreated, MSC, Au-Steroid, MSC-Au-Steroid). Following 72 h stimulation with anti-CD3 (1 µg mL⁻¹), T cell proliferation was assessed by BrdU incorporation (F), and IFN-γ production was quantified in culture supernatants by ELISA (G). Data are presented as the mean \pm SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05.

References

1. Sekiya I, Katano H, Guermazi A, Miura Y, Okanouchi N, Tomita M, et al. Association of Aldetermined Kellgren-Lawrence grade with medial meniscus extrusion and cartilage thickness by Al-based 3D MRI analysis in early knee osteoarthritis. Sci Rep. 2023;13(1):20093.